Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255203 | 0.81 | CTSK (0.40) | CYP17A1CA1CA2NAMPTATR | |
| SCHEMBL21754350 | 0.81 | MIF (0.38) | CYP17A1CA1CA2NAMPTATR | |
| SCHEMBL20542063 | 0.80 | CA1 (0.40) | CYP17A1CA1CA2NAMPTATR | |
| SCHEMBL21754348 | 0.78 | CA1 (0.36) | CYP17A1CA1CA2NAMPTATR | |
| SCHEMBL20557969 | 0.75 | SMN1; SMN2 (0.55) | CA1CA2NAMPTSMN1; SMN2NR1H2 | |
| SCHEMBL18209708 | 0.75 | MAPK8 (0.47) | CYP17A1NAMPTATRRXFP1METAP1 | |
| SCHEMBL20268132 | 0.74 | CYP17A1 (0.36) | CYP17A1NAMPTATRRXFP1METAP1 | |
| SCHEMBL15813381 | 0.72 | CYP4A11 (0.39) | — | |
| SCHEMBL15813380 | 0.72 | CYP17A1 (0.34) | CYP17A1CA1CA2NAMPTLMNA | |
| SCHEMBL16845713 | 0.70 | AXL (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-113272305-A | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2021-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CYP17A1 104/4885CA1 3888/4885CA2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.